Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol

Journal of Internal Medicine

Volumn 246, Issue 1, 1999, Pages 1-9

  Vega, Gloria Lena ^a,b,c   Von Bergmann, K ^d   Grundy, S M ^a,b,c   Blumenschein, S ^b   Carter, N B ^a,b,c   Laeis, P ^d   Lindenthal, B ^d   Von Bergmann, J ^d   Simatupang, A ^d   Lutjohann, D ^d   Adams Huet, B ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Department of Clinical Nutrition ^*  (United States)

^c North Texas Healthcare System   (United States)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

Apolipoprotein metabolism; Hypercholesterolemia; Lifibrol

Indexed keywords

APOLIPOPROTEIN B; BILE ACID; CHOLESTEROL; LIFIBROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVALONIC ACID; SIMVASTATIN; STATIN;

BILE ACID METABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LIPID METABOLISM; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

EID: 0032798184     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00536.x     Document Type: Review

References (27)

1. Hasibeder H, Staab HJ, Seibel K, Heibel B, Schmidle G, Marz W. Clinical pharmacology of the hypercholesterolemic agent K12.148 (lifibrol) in healthy volunteers. Eur J Clin Pharmacol 1991; 40: 91-4.
2. Schwandt P. Elsasser R, Schmidt C, Gertz B, Heil M, Augustin J, et al. Safety and efficacy of lifibrol upon four-week administration to patients with primary hypercholesterolemia. Eur J Clin Pharmacol 1994; 47: 133-8.
3. Locker PK, Jungbluth GL, Francom SF, Hughes GS, for the Lifibrol Study Group. Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Clin Pharmacol Ther 1995; 57: 73-88.
4. Scharnagl H, Martz W, Schliack M, Loser R, Gross W. A novel assay for cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase activity using reversed-phase ion-pair chromatography: demonstration that Lifibrol (K12.148) modulates the enzyme activity. J Lipid Res 1995; 16: 622-7.
5. Schliack M, Loser R, Seibel L, Blay KH. Hypolipemic activity of K12.148 in rats, marmosets and pigs. Artery 1989; 16: 90-104.
6. Bell FP, John JCS. Action of the new hypolipidemic agent lifibrol (K12.148) on lipid homeostasis in normal rats: plasma lipids, hepatic sterologenesis, and the fate of injected [14C] acetate. Lipids 1993; 28: 1079-85.
7. Krause BR, Bousley R, Kieft K, Robertson D, Stanfield R, Urda E, et al. Comparison of lifibrol to other lipid-regulating agents in experimental animals. Pharmacol Res 1994; 29: 345-57.
8. Bell FO. Effect of lipid-lowering drug lifibrol on lipid metabolism in rat macrophages and in atherosclerotic arteries from swine and WHHL rabbits, in vitro. Implication in atherogenesis. Biochem Pharmacol 1993; 46: 1475-80.
9. Uauy R, Vega GL, Grundy SM, Bilheimer DM. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr 1988; 113: 387-92.
10. Roeschlau P, Bernt E, Gruber W. Enzymatic determination of total cholesterol in serum. Z Klin Chem Klin Biochem 1974; 12: 226-7.
11. McGowan MW, Artis JD, Strandbergh DR, Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983; 29: 538-42.
12. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemia patients with hypoalphalipoproteinemia. Arch Int Med 1994; 154: 73-82.
13. Tato F, Vega GL, Tall AR, Grundy SM. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1995; 15: 112-20.
14. Tato F, Vega GL, Grundy SM. Determinants of plasma HDL cholesterol in hypertriglyceridemic patients: role of cholesterol ester transfer protein and lecithin cholesterol acyl transferase. Arterioscler Thromb Vasc Biol 1997; 17: 56-63.
15. Vega GL, Grundy SM. Two patterns of LDL metabolism in normotriglyceridemic patients with hypoalphalipoproteinemia. Arteriosclerosis Thrombosis 1993; 13: 579-89.
16. Matthews CME. The theory of tracer experiments with iodine L3II-labeled plasma proteins. Phys Med Biol 1957; 2: 36-53.
17. Souci SW, Fachmann W, Kraut H. Composition and Nutrition Tables 1989/1990 In Wissenschaftliche-Verlagsgesellschaft mbH. Stuttgart, Germany (software).
18. Czubayko F, Beumers B, Lammsfuss S, Lutjohann D, von Bergmann K. A simplified micromethod for quantitation of fecal excretion of neutral and acidic sterols of outpatient studies in humans. J Lipid Res 1997; 32: 1861-7.
19. Lutjohann D, Meese CO, Crouse JR, 3rd von Bergmann K. Evaluation of deuterated cholesterol and deuterated sitostanol for measurement of cholesterol absorption in humans. J Lipid Res 1993; 34: 1039-46.
20. Lindenthal B, von Bergmann K. Determination of urinary mevalonic acid using isotope dilution technique. Bio Mass Spectrom 1994; 23: 445-50.
21. Endo A. The discovery and development of HMG-CoA reductase inhibitor. J Lipid Res 1992; 33: 1569-82.
22. Gurndy SM, Bilheimer DW. Influence of inhibition of 3-hydroxy-3-methylglutaryl CoA by reductase by mevinolin in familial hypercholesterolemia heteroxygotes: Effects of cholesterol balance. Proc Natl Acad Sci (USA) 1984; 81: 2538-42.
23. Grundy SMEH, Ahrens JR, EH, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971; 78: 94-121.
24. Grundy SM, Mok HY. Determination of cholesterol absorption in man by intestinal perfusion. J Lipid. Res 1977; 18: 263-71.
25. Becker M, Staab, D, von Bergmann K. Treatment of severe familial hypercholesterulemia in childhood with sitosterol and sitostanol. J Pediatr 1993; 122: 292-6.
26. Miettinen TA, Puska P, Gylling H, Vanhanen, H. Vartiainen E. Reduction in serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995; 333: 1308-12.
27. Kesaniemi YA, Grundy SM. Turnover of low density lipoproteins during inhibition of cholesterol absorption by neomycin. Arteriosclerosis 1984; 4: 41-8.